Xiaolong Xu

2.6k citations
83 papers · 1.9k indexed · 1 hit paper · h-index 23

Xiaolong Xu

79 papers receiving 1.9k citations

Hit Papers

CircRNA inhibits DNA damage repair by interacting with ho...280202020262022202450100150200250

Peers

Xiaolong Xu
Comparison fields: 5 of 113
  • Cancer Research 514
  • Molecular Biology 1.1k
  • Orthopedics and Sports Medicine 126
  • Genetics 135
  • Pathology and Forensic Medicine 209
Replace Hengwei Zhang with:
Hengwei Zhang China
Hua Wu China
Anling Liu China
Jia Cao China
Zhenhong Ni China
Min Jin China
Megan Weivoda United States
Merissa Olmer United States
Qi Guo China
Bin Zhu China
Xiaolong Xu relative to Hengwei Zhang China Hengwei Zhang's profile →
Citations per field
00.5×1.5×1.9×
Hengwei Zhang · 1×
Citations per year

Countries citing papers authored by Xiaolong Xu

Since Specialization
Citations

This map shows the geographic impact of Xiaolong Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaolong Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaolong Xu more than expected).

Fields of papers citing papers by Xiaolong Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaolong Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaolong Xu. The network helps show where Xiaolong Xu may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Xiaolong Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Xiaolong Xu Line = papers co-authored together Xiaolong Xu links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20241
2 20245
3 20242
4 20240
5 20237
6 202311
7 20239
8 20225
9 202212
10
CircRNA inhibits DNA damage repair by interacting with host genebreakdown →
2020280
11 202011
12 201921
13 201992
14 201936
15 201928
16 20188
17 2018220
18 201716
19 201712
20 201588

About Xiaolong Xu

Xiaolong Xu is a scholar working on Otorhinolaryngology, Cancer Research and Orthopedics and Sports Medicine, having authored 83 papers that have together received 1.9k indexed citations. Recurring topics across this work include Head and Neck Cancer Studies (5 papers), Wnt/β-catenin signaling in development and cancer (5 papers), Bone Metabolism and Diseases (5 papers), MicroRNA in disease regulation (5 papers), Mesenchymal stem cell research (5 papers), RNA Research and Splicing (5 papers), Genomics, phytochemicals, and oxidative stress (4 papers) and Cancer-related Molecular Pathways (4 papers). The work is most often cited by research in Cancer Research (514 citations), Molecular Biology (1.1k citations) and Orthopedics and Sports Medicine (126 citations). Xiaolong Xu has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Lei Wei, Yang Gao, Yihao Tian, Jingwei Zhang, Liu Yang, Xiaoning Yuan, Jiang Peng, Zhuojing Luo, Weinan Yin and Chao Zheng. Their work appears in journals such as SHILAP Revista de lepidopterología, PLoS ONE and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026